🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#News for #Media and #Investors: Today, we announced that the U.S. FDA has approved our meningococcal vaccine. Find out more here: gsk.to/4hA4CIP

We’re looking forward to attending #AAAAI25 and WAO joint congress to share our latest research in severe uncontrolled #asthma. Together, our innovation is paving a path forward for patients living with and managing respiratory diseases.

News for #investors and #media: ViiV Healthcare, our specialist HIV company, is presenting more than 70 abstracts at #CROI2025, reinforcing our leadership in long-acting innovation and supporting our ambition to end HIV and AIDS for good. Find out more: gsk.to/4hhqFTt

#News for #investors and #media: New data has been presented at #CROI2025 on the innovative pipeline of our specialist HIV company, ViiV Healthcare. 🔗 Find out more: gsk.to/3DM3Fyf

Our commitment to advancing new treatment options is inspired by patients like Andrea, who was diagnosed with #endometrialcancer in 2017. Watch to learn more about her story and stay tuned as we share our latest innovations in gynecologic cancer research at this year's #SGOmtg.

#News for #Media and #Investors: Today we announced that our oral antibiotic for uncomplicated urinary tract infections has been approved by US Food and Drug Administration (FDA). Learn more: gsk.to/3QNxYaP

Construction has begun to expand our Pennsylvania site where we’re using smart manufacturing to reach people who need our medicines and vaccines better and faster. Thank you for joining us today, Rick Siger! 🏭Read about our largest US manufacturing investment to date:

#News for #Media and #Investors Two of our vaccines have received new recommendations from the US Advisory Committee on Immunization Practices (ACIP). These recommendations will be reviewed for official adoption. Learn more at: gsk.to/4ltr4pf

Our CEO Emma Walmsley announces our strong Q1 2025 performance, demonstrating the quality, strength and resilience of our portfolio. More information for media and investors: gsk.to/4iE8HLC $GSK #FYResults

Explore the key highlights from our Q1 2025 performance. More information for media and investors: gsk.to/42TtzIS. $GSK

#News for #media and #Investors: Today we announced our sponsorship of “Pretty Hurts” a new Lifetime Original Movie and the latest extension of our Ask2BSure public health campaign. Learn more: gsk.me/3YCxeK9

With over 40 abstracts, including 4 late-breaker submissions, this data line-up is a testament to our long-term focus on a broad range of areas where we can help improve outcomes for patients suffering from complex respiratory diseases. Precil Varghese shares more about our

We’re at #ATS2025 and excited to share our latest research across 40 abstracts from our portfolio of inhaled therapies, biologics and pipeline assets. GSK’s own Court Horncastle shares his thoughts on the key data and why ATS is so important to getting ahead of respiratory

#News for #investors and #media: Today we announced our anti IL-5 biologic treatment for people living with COPD has been approved by the US Food and Drug Administration (FDA). Learn more: gsk.to/4jk9KRx

At the The Wall Street Journal's "The Future of Everything", our CEO Emma Walmsley joined leaders across business, tech, sports, and style to tackle tomorrow's challenges, including the future of drug discovery using cutting-edge tech and the impact of prevention on disease. #TheFutureOfEverything

#News for #investors and #media: At #ASCO2025 in Chicago, IL and #EHA2025 in Milan, Italy we will be presenting findings across our oncology pipeline and portfolio in more than 60 abstracts. Learn more: gsk.to/43jGx4j

We’re excited to present 18 abstracts at #ASCO2025 that highlight our latest innovations and advances in #cancer research.